

Chor Sang Chim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1580102/publications.pdf>

Version: 2024-02-01

41
papers

799
citations

430874

18
h-index

526287

27
g-index

41
all docs

41
docs citations

41
times ranked

1492
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2760-2767.	3.6	89
2	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NF κ B pathway. <i>Molecular Cancer</i> , 2013, 12, 173.	19.2	66
3	¹¹ C-Acetate PET/CT for Metabolic Characterization of Multiple Myeloma: A Comparative Study with ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2014, 55, 749-752.	5.0	45
4	Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. <i>Molecular Cancer</i> , 2015, 14, 175.	19.2	40
5	Molecular detection of minimal residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 2018, 181, 11-26.	2.5	39
6	Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. <i>Journal of Translational Medicine</i> , 2011, 9, 197.	4.4	38
7	Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2014, 12, 52.	4.4	35
8	Methylation of <i>miR-155-3p</i> in mantle cell lymphoma and other non-Hodgkin's lymphomas. <i>Oncotarget</i> , 2014, 5, 9770-9782.	1.8	30
9	DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. <i>Epigenomics</i> , 2015, 7, 985-1001.	2.1	29
10	Epigenetic silencing of tumor suppressor long non-coding RNA <i>BM742401</i> in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 82400-82410.	1.8	26
11	<i>LDH</i> is an adverse prognostic factor independent of <i>ISS</i> in transplant-eligible myeloma patients receiving bortezomib-based induction regimens. <i>European Journal of Haematology</i> , 2015, 94, 330-335.	2.2	25
12	Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2019, 9, 449.	2.8	25
13	DNA methylation of tumor-suppressor miRNA genes in chronic lymphocytic leukemia. <i>Epigenomics</i> , 2015, 7, 461-473.	2.1	24
14	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. <i>Clinical Epigenetics</i> , 2019, 11, 71.	4.1	23
15	Epigenetic inactivation of <i>DAPK1</i> , <i>p14^{ARF}</i> , <i>mir-34a</i> and <i>-34b/c</i> in acute promyelocytic leukaemia. <i>Journal of Clinical Pathology</i> , 2014, 67, 626-631.	2.0	21
16	Epigenetic silencing of tumor suppressor <i>miR-3151</i> contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. <i>Oncotarget</i> , 2015, 6, 44422-44436.	1.8	21
17	RANKL expression in myeloma cells is regulated by a network involving RANKL promoter methylation, DNMT1, microRNA and TNF α in the microenvironment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 1834-1838.	4.1	20
18	Infrequent DNA methylation of <i>miR-9-1</i> and <i>miR-9-3</i> in multiple myeloma. <i>Journal of Clinical Pathology</i> , 2015, 68, 557-561.	2.0	20

#	ARTICLE	IF	CITATIONS
19	High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. <i>Journal of Hematology and Oncology</i> , 2016, 9, 107.	17.0	20
20	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , 2018, 59, 2305-2317.	1.3	18
21	Epigenetic silencing of LPP/miR-28 in multiple myeloma. <i>Journal of Clinical Pathology</i> , 2018, 71, 253-258.	2.0	15
22	Epigenetic silencing of EVL/miR-342 in multiple myeloma. <i>Translational Research</i> , 2018, 192, 46-53.	5.0	14
23	Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 728-737.	2.4	14
24	Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. <i>Journal of Hematology and Oncology</i> , 2012, 5, 28.	17.0	13
25	Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL. <i>Cancer Cell International</i> , 2013, 13, 122.	4.1	11
26	Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. <i>Scientific Reports</i> , 2018, 8, 13522.	3.3	11
27	Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy. <i>Clinical Epigenetics</i> , 2020, 12, 150.	4.1	11
28	Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. <i>Cancer Cell International</i> , 2020, 20, 403.	4.1	11
29	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019, 98, 941-949.	1.8	9
30	miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin's lymphoma: novel targets with impact on ERK signaling and cell migration. <i>Cell Communication and Signaling</i> , 2021, 19, 62.	6.5	8
31	Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients. <i>Journal of Translational Medicine</i> , 2010, 8, 124.	4.4	7
32	GI manifestations of mantle cell lymphoma. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 931-933.	1.0	3
33	Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival. <i>Hematological Oncology</i> , 2014, 32, 205-211.	1.7	3
34	3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. <i>Hematology</i> , 2021, 26, 652-655.	1.5	3
35	Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR. <i>Frontiers in Oncology</i> , 2020, 10, 611021.	2.8	3
36	The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210820.	2.5	3

#	ARTICLE	IF	CITATIONS
37	Survival of >20 years in a myeloma patient with an unusual combination of t(14;16) and hyperdiploidy: A case report. <i>Oncology Letters</i> , 2013, 6, 1663-1664.	1.8	2
38	Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses. <i>Clinical Epigenetics</i> , 2018, 10, 158.	4.1	2
39	A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 7009.	3.3	2
40	Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma. <i>Hematology</i> , 2019, 24, 533-537.	1.5	0
41	PAD Induction Therapy Followed by Autologous Peripheral Blood Stem Cell Transplant (APBSCT) as Upfront Treatment for Myeloma (MM) in Chinese Patients.. <i>Blood</i> , 2009, 114, 4367-4367.	1.4	0